Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Curevac Gmbh patents


Recent patent applications related to Curevac Gmbh. Curevac Gmbh is listed as an Agent/Assignee. Note: Curevac Gmbh may have other listings under different names/spellings. We're not affiliated with Curevac Gmbh, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Curevac Gmbh-related inventors


 new patent  Immobilized poly(n)polymerase

The present invention relates to an immobilized poly(n)polymerase (pnp), methods of producing said pnp and uses thereof. Further disclosed is an enzyme reactor and kit comprising the pnp for producing polynucleotidylated ribonucleic acid poly(n)rna)molecules which are useful in gene therapy, immunotherapy, protein replacement therapy and/or vaccination.. ... Curevac Gmbh

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l; (lys)m; (his)n; (orn)o; (xaa)x with the majority of residues being selected from arg, lys, his, orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Gmbh

New targets for rna therapeutics

The present invention relates to a method for treating or preventing a disease, disorder or condition by administration of a polynucleotide, e.g. A modified rna, encoding a peptide or protein related to this disease, disorder or condition. ... Curevac Gmbh

Prime-boost regimens involving administration of at least one mrna construct

The present invention relates to prime-boost regimens that involve the administration of at least one mrna construct, such as the use of such constructs in “boost” administration subsequently to “prime” administration of certain other antigenic composition(s). Such inventive regimens may, in particular, be useful for the induction of an immune response in a subject, and/or the vaccination of such subject against infection from one or more pathogens, and/or the treatment or prevention of one or more diseases or conditions, including a tumour or cancer, allergy or autoimmune conditions, and/or a disease or condition associated with infection from a pathogen. ... Curevac Gmbh

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Gmbh

Combination of vaccination and inhibition of mhc class i restricted antigen presentation

The present invention relates to a vaccine/inhibitor combination comprising as a vaccine at least one antigen and as an inhibitor at least one inhibitor of the major histocompatibility complex (mhc) class i restricted antigen presentation. The present invention furthermore relates to a method of vaccination of a mammal using the inventive vaccine/inhibitor combination. ... Curevac Gmbh

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein

The present application describes a coding nucleic acid sequence, particularly a messenger rna (mrna), comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g. ... Curevac Gmbh

Artificial nucleic acid molecules for improved protein expression

The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3′-utr comprising at least one poly(a) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3′-utr comprising at least one poly(a) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. ... Curevac Gmbh

Ebolavirus and marburgvirus vaccines

The present invention relates to an mrna sequence, comprising a coding region, encoding at least one antigenic peptide or protein derived from the glycoprotein (gp) and/or the matrix protein 40 (vp40) and/or the nucleoprotein (np) of a virus of the genus ebolavirus or marburgvirus or a fragment, variant or derivative thereof. Additionally, the present invention relates to a composition comprising a plurality of mrna sequences comprising a coding region, encoding at least one antigenic peptide or protein derived from the glycoprotein (gp) and/or the matrix protein 40 (vp40) and/or the nucleoprotein (np) of a virus of the genus ebolavirus or marburgvirus or a fragment, variant or derivative thereof. ... Curevac Gmbh

Vaccination in newborns and infants

The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.. ... Curevac Gmbh

Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant

The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid molecule and as a preferably non-toxic and non-immunogenic polymeric carrier disulfide-crosslinked cationic components for use as an immunostimulating agent or as an adjuvant, wherein the polymeric carrier cargo complex is administered in combination with at least one second nucleic acid molecule, which encodes a protein or peptide. The inventive polymeric carrier cargo complex administered in combination with the second nucleic acid molecule allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an innate and/or adaptive immune response, preferably dependent on the nucleic acid to be transported as a cargo and on the second nucleic acid molecule. ... Curevac Gmbh

Artificial nucleic acid molecules for improved protein or peptide expression

The invention relates to an artificial nucleic acid molecule comprising at least one 5′utr element which is derived from a top gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. ... Curevac Gmbh

Reversible immobilization and/or controlled relase of nucleic acid containing nanoparticles by (biodegradable) polymer coatings

The present invention relates to nanoparticles comprising nucleic acids coated with a (biodegradable) polymer for reversible immobilization and/or controlled release of the nucleic acid comprising nanoparticles. Furthermore, the present invention is directed to medical or diagnostic devices, particularly stents and implants coated by a (biodegradable) polymer with the nucleic acid comprising nanoparticles for reversible immobilization and/or controlled release. ... Curevac Gmbh

Respiratory syncytial virus (rsv) vaccine

The present invention relates to an mrna sequence, comprising a coding region, encoding at least one antigenic peptide or protein of rsv infections respiratory syncytial virus (rsv) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mrna sequences comprising a coding region, encoding at least one antigenic peptide or protein of rsv infections respiratory syncytial virus (rsv) or a fragment, variant or derivative thereof. ... Curevac Gmbh

07/27/17 / #20170211068

Immunostimulation by chemically modified rna

The present invention relates to an immunostimulating agent comprising at least one chemically modified rna. The invention furthermore relates to a vaccine which comprises at least one antigen in combination with the immunostimulating agent. ... Curevac Gmbh

07/20/17 / #20170202957

Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof

The present invention relates to an immunostimulatory composition comprising a) an adjuvant component, comprising or consisting of at least one (m)rna, complexed with a cationic or polycationic compound, and b) at least one free mrna, encoding at least one therapeutically active protein, antigen, allergen and/or antibody, wherein the immunostimulatory composition is capable to elicit or enhance an innate and optionally an adaptive immune response in a mammal. The inventive immunostimulatory composition may be a pharmaceutical composition or a vaccine. ... Curevac Gmbh

07/13/17 / #20170196969

Vaccination in newborns and infants

The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.. ... Curevac Gmbh

07/13/17 / #20170196967

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. ... Curevac Gmbh

06/29/17 / #20170182150

Vaccination with mrna-coded antigens

The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.. ... Curevac Gmbh

06/29/17 / #20170182081

Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids

The present invention is directed to (the use of) a solution containing at least one nucleic acid (sequence) and free mannose for lyophilization, transfection and/or injection, particularly of rna and mrna. The inventive solution exhibits a positive effect on stabilization of the nucleic acid (sequence) during lyophilization and storage but also leads to a considerable increase of the transfection efficiency of a nucleic acid. ... Curevac Gmbh

05/11/17 / #20170128549

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Gmbh

04/27/17 / #20170114378

Methods and means for enhancing rna production

The present invention relates to a method for synthesizing an rna molecule of a given sequence, comprising the step of determining the fraction (1) for each of the four nucleotides g, a, c and u in said rna molecule, and the step of synthesizing said rna molecule by in vitro transcription in a sequence-optimized reaction mix, wherein said sequence-optimized reaction mix comprises the four ribonucleoside triphosphates gtp, atp, ctp and utp, wherein the fraction (2) of each of the four ribonucleoside triphosphates in the sequence-optimized reaction mix corresponds to the fraction (1) of the respective nucleotide in said rna molecule, a buffer, a dna template, and an rna polymerase. Further, the present invention relates to a bioreactor (1) for synthesizing rna molecules of a given sequence, the bioreactor (1) having a reaction module (2) for carrying out in vitro rna transcription reactions in a sequence-optimized reaction mix, a capture module (3) for temporarily capturing the transcribed rna molecules, and a control module (4) for controlling the infeed of components of the sequence-optimized reaction mix into the reaction module (2), wherein the reaction module (2) comprises a filtration membrane (21) for separating nucleotides from the reaction mix, and the control of the infeed of components of the sequence-optimized reaction mix by the control module (4) is based on a measured concentration of separated nucleotides.. ... Curevac Gmbh

03/09/17 / #20170065727

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Gmbh

03/02/17 / #20170056529

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein, particularly for the use in gene therapy. ... Curevac Gmbh

02/02/17 / #20170029847

Artificial nucleic acid molecules

The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-utr) element comprising a nucleic acid sequence which is derived from the 3′-utr of a ribosomal protein gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. ... Curevac Gmbh

02/02/17 / #20170028059

Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates

The present invention is directed to a composition or vaccine composition comprising a) an adjuvant component comprising or consisting of at least one immunostimulatory nucleic acid sequence, complexed with a complexing agent; b) an antigen, preferably a protein or peptide antigen and/or a nucleic acid sequence encoding said antigen; and c) a carrier molecule for combined packaging the adjuvant component and the antigen. The present invention is also directed to the first medical use of such a composition or vaccine composition and to the second medical use of such a composition or vaccine composition or components thereof for the treatment of diseases, such as infectious or cancer or tumour diseases as defined herein. ... Curevac Gmbh

01/19/17 / #20170014496

Combination of vaccination and ox40 agonists

The present invention relates to a vaccine/agonist combination comprising an rna vaccine comprising at least one rna comprising at least one open reading frame (orf) coding for at least one antigen and a composition comprising at least one ox40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. ... Curevac Gmbh

01/05/17 / #20170000871

Composition for treating prostate cancer (pca)

The present invention relates to an active (immunostimulatory) composition comprising at least one rna preferably an mrna, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of psa (prostate-specific antigen), psma (prostate-specific membrane antigen), psca (prostate stem cell antigen), and steap (six transmembrane epithelial antigen of the prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (pca), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto. ... Curevac Gmbh

01/05/17 / #20170000870

Combination therapy for immunostimulation

The present invention relates to a method for immunostimulation in a mammal which comprises a. Administration of at least one mrna containing a region which codes for at least one antigen of a pathogen or at least one tumour antigen, and b. ... Curevac Gmbh

01/05/17 / #20170000858

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(orn)o;(xaa)x with the majority of residues being selected from arg, lys, his, orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna. ... Curevac Gmbh








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Curevac Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Curevac Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###